Registration Requirements

The registration of medicinal products is governed by relative values which cannot be clearly defined or limited, for example by ethical considerations and the endeavour to ensure the best possible quality and safety of pharmaceuticals. What is possible and achievable, may soon become a standard by which subsequent products will be measured. This leads to continuous and desirable improvements, but since there is no limit, very costly and undesirable extremes may be another consequence. According to today s standards, the most successful and beneficial pharmaceutical products, such as the vaccinia virus vaccine, live poliovirus vaccine and other live vaccines, would probably not be registrable for a wide-spread use in humans. 

The technical and analytical progress of the recent decades as well as the increasing safety requirements became standards which have been layed down in various legal documents and persuasive 

Triggered by the consolidated EEC regulations, attempts to harmonize the international registration requirements finally found sufficient support and led to the International Conference on 

Pharmaceuticals for Human Use (ICH), which at the moment concentrates on a harmonization between the leading pharmaceutical producer and user countries, the USA, EEC and Japan. The ICH can only identify the differences and make recommendations for 

To achieve the necessary level of information which is required to develop a product, the relevant guidelines have to be studied and compared with a specific product and question in mind, and latest trends and opinions have to be gathered from experienced people in the field. 

---

In Venezuela, there is no official fast-track system. However, brief-mode registration is available for generic products for which a bioavailabilily study has been undertaken. Similarly, Malaysia has an abridged procedure for registration of products classified as non-scheduled poisons. This type of simplified procedure does not, in essence, differ from the use of less stringent registration requirements for certain categories of products as seen, for example, for herbal medicines in Australia and the Netherlands. 

Registration requirements and process Information required and degree of assessment... 

Registration requirements, SOPs and decision criteria are documented to ensure transparency of the regulatory process and to facilitate communication between the regulatory authority, the pharmaceutical industry and the public. 

Finally, to avoid the parallel use of similar but not identical method validation studies to fulfil the registration requirements, e.g., of the EU, US Environmental Protection Agency (EPA) or Japanese authorities, an adaptation of different data requirements for residue analytical methods for post-registration control and monitoring purposes would help to save resources. 

Economic poisons are probably more closely regulated than any other class of material generally sold. In addition to registration required before a product can be sold, and continuous sampling and investigation after it is once put on the market, each reported case of injury is studied to determine if the material was at fault or if there was misrepresentation made in recommendations for use of the product. Two cases of reported injury that were of particular interest come to mind. 

Environmental chemistry analytical methods, 9 442 corporate programs, 9 456 457 of Dyes 9 431-463 effluent treatment, 9 432 437 fate of dyes, 9 437-442 pesticide registration requirements for, 18 545-547... 

Pesticide mobility studies, 18 546 Pesticide registration requirements, in the United States, 18 543-550 Pesticide regulation, 18 524, 536-543. See also Pesticide regulations role of international organizations in,... 

Product chemistry, pesticide registration requirements for, 73 544 Product contact utilities, 77 44-45 Product cost, 9 531-534 Product design... 

Residential exposure, pesticide registration requirements for, 73 549-550 Resident time distribution (RTD), in reactors, 27 355-356 Residual property, 24 659... 

Residue chemistry, pesticide registration requirements for, 18 544-545 Residue curve maps (RCM), 8 790-793 22 302, 303... 

Yakuji Nippo, Ltd. (1991). Drug Registration Requirements in Japan. Yakuji Nippo, Ltd., Tokyo, Japan. 

Chronic studies (those that last six or nine months or a year) may also be conducted for the above purposes but are primarily done to fulfill registration requirements for drugs that are intended for continuous long-term (lifetime) use or frequent intermittent use. 

Registration requirements for purchasing, possessing, and using explosives have been revised with increased restrictive requirements in recent years [149]. Increased scrutiny and regulation of commercially available components of lEDs can be anticipated. 

Registration requires manufacturers and importers of chemicals to obtain relevant information on their substances and to use that data to manage them safely. 

Evaluation is undertaken by the ECHA (see below) to evaluate testing proposals made by industry or to check compliance with the registration requirements. The ECHA will also coordinate substance evaluation by the authorities to investigate chemicals with perceived risks. This assessment may be used later to prepare proposals for restrictions or authorization. Substances with properties of very high concern will be made subject to authorization the ECHA will publish a list containing such candidate substances. Applicants will have to demonstrate that risks associated with uses of these substances are adequately controlled or that the socioeconomic benefits of their use outweigh the risks and there are no suitable alternative substitute substances or technologies. 

The standard conditions of registration require the sponsor to inform the TGA of any adverse drug reactions and safety alerts related to their product of which they become aware. 

In the next section we are concentrating on giving general overview of registration requirements for two major groups of medicines innovative (originator) and multisource (generic) medicines. 

Require background check for private saies Mandatory handgun registration Require new handguns be personalized Mandatory background check 2 and five-day waiting period Limit one handgun per... 

The Registration, Evaluation, Authorisation and Restriction of Chemical substances (REACH) regulations came into force on June 1, 2007. At that time, it was estimated that there were approximately 100,000 existing chemicals, of which approximately 30,000 were marketed in volumes at or above 1 tonne per year. For these 30,000 substances, a registration dossier must be submitted. The registration requirements depend on the tonnage thresholds, as follows ... 

Trials during clinical development are designed to meet registration requirements rather than to answer such questions. 

The two most contentious aspects of REACH have been the registration requirements and the authorization process. While no one has argued that substances should not have to be registered, there have been many arguments about the amount of data that must be submitted in the registration dossiers and about how to deal with substances contained in manufactured articles imported from outside the EU. The public availability of information has also been an issue. The focus of the debate about authorization was whether authorizations should be granted where an alternative was available. The debate here can be seen as an argument between risk-based and precautionary approaches. 

Many aspects of REACH are to be reviewed within a few years of REACH coming into force in June 2007- These include Annex I, which sets out the requirements for CSRs (to be reviewed within 12 months) Annex XIII (criteria for identification of PBT and vPvB substances) (within 18 months) the authorization of endocrine-disrupting substances (after 6 years) and the registration requirements for substances below 10 tonnes (after 12 years). These reviews, along with the fact that the implementation of REACH will depend on how its provisions are interpreted and the guidance documents that are produced, mean that it is very difficult to say what REACH will mean in practice for the production and use of synthetic chemicals and the protection of human health and the environment from their harmful effects. 

Organisation for Economic Cooperation and Development (OECD) (2002) Guidance for the Registration Requirements for Pheromones and Other Semiochemicals... 

In 1993, the Global Harmonization of Standards (GHOST) discussion document was published by FEDESA. This sets out a program for the international harmonization of registration requirements for veterinary pharmaceuticals and biologicals. 

---